---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-017841"
form_type: "8-K"
ticker: "UNCY"
cik: "0001766140"
company_name: "Unicycive Therapeutics, Inc."
filed_at: "2023-03-06T23:59:59+00:00"
generated_at: "2026-06-18T11:58:30.826854+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Unicycive raises up to $130M in private placement led by Vivo Capital for Renazorb launch

## Summary
- $30M upfront from Series A-1 Convertible Preferred Stock; up to $100M additional via milestone-linked warrants.
- Tranche A warrants ($25M) exercisable upon FDA approval of Renazorb; Tranche B ($25M) upon TDAPA approval; Tranche C ($50M) after four quarters of commercial sales.
- Gaurav Aggarwal, MD (Vivo Capital) appointed to Board of Directors effective at closing.
- Company to adopt dividend policy paying at least 75% of annual net cash flow from operations to all stockholders post-approval and commercial sales.
- Proceeds to support NDA submission for Renazorb (hyperphosphatemia) and potential U.S. commercial launch.

## SEC filing metadata
- accession: 0001213900-23-017841
- form_type: 8-K
- ticker: UNCY
- cik: 0001766140
- company_name: Unicycive Therapeutics, Inc.
- filed_at: 2023-03-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 5.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1766140/000121390023017841/0001213900-23-017841-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1766140/000121390023017841/ea174702-8k_unicycive.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-017841
- JSON: https://secwatch.observer/filing/0001213900-23-017841.json
- Plain text: https://secwatch.observer/filing/0001213900-23-017841.txt

## Key facts
- Executive change
  Gaurav Aggarwal was appointed as Director at Unicycive Therapeutics, Inc..
  - Action: appointed
  - Role: Director
  source text: effective as of the closing of the Offering, Gaurav Aggarwal, MD shall be appointed to the Company’s Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023017841/0001213900-23-017841-index.htm
- Governance Changes
  Unicycive Therapeutics, Inc.: Gaurav Aggarwal, MD was appointed to the Board of Directors effective upon closing of the offering, with standard non-employee director compensation and indemnification (effective 2023-03-06).
  - Effective: 2023-03-06
  source text: Pursuant to the terms of the Purchase Agreement, effective as of the closing of the Offering, Gaurav Aggarwal, MD shall be appointed to the Company’s Board of Directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023017841/0001213900-23-017841-index.htm
- Material Agreements
  Unicycive Therapeutics, Inc. entered into Purchase Agreement with certain accredited investors valued at $30 million (effective 2023-03-03).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: certain accredited investors
  - Value: $30 million
  - Effective: 2023-03-03
  source text: On March 3, 2023, Unicycive Therapeutics , Inc. (the " Company ") entered into a securities purchase agreement (the " Purchase Agreement ") with certain accredited investors (the " Investors "), pursuant to which the Company agreed to issue and sell, in a private placement (the " Offering "), 30,190 shares of Series A-1 Convertible Preferred Stock, par value $0.001 per share (the " Series A-1 Preferred Stock "), for an aggregate offering price of $30 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1766140/000121390023017841/0001213900-23-017841-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.